Syncom Formulations (India) Q2 Results 2026: PAT ₹27 Cr +61%
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹142Cr
- +16.8% YoY
- +13.2% QoQ
- Net profit
- ₹27Cr
- +60.5% YoY
- +7.2% QoQ
- Margin
- 22.5%
- +7.4 pp YoY
- +1.6 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Syncom Formulations (India) Ltd Q2 FY27 key numbers
- Revenue
- Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026): ₹14,821.08 lakhs (Unaudited).
As stated in Syncom Formulations (India) Ltd's Q2 FY27 results statement · published 14 Nov 2026. Reported figures, not investment advice.
Based on Syncom Formulations (India) Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026): ₹14,821.08 lakhs (Unaudited). Quarterly EBITDA: Rs. 3,602.77 lakhs.
From Syncom Formulations (India) Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Syncom Formulations (India)'s revenue grow in the September 2026 quarter?
What happened to Syncom Formulations (India)'s margins in Q2 FY27?
Quarterly EBITDA: Rs. 3,602.77 lakhs
Locked: what Syncom Formulations (India) Ltd said on margins
Also locked on this page: capex, fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Syncom Formulations (India) planning?
See what Syncom Formulations (India) Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Syncom Formulations (India) raising money or cutting debt?
On page 12 (Consolidated Cash Flow Statement), there is a net increase in borrowings of Rs. 5551.06 lakhs…
Locked: what Syncom Formulations (India) Ltd said on fundraising
Also locked on this page: margins, capex, order book
Free account, 30 seconds. No card needed.
How big is Syncom Formulations (India)'s order book?
See what Syncom Formulations (India) Ltd said on order book & pipeline — free account, 30 seconds.
Syncom Formulations (India) Ltd — Quarterly revenue & net profit
Syncom Formulations (India) Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 142 | 122 | +16.8% | 126 | +13.2% |
| Operating profit (EBITDA) | 32 | 18 | +73.5% | 26 | +21.8% |
| Operating margin | 22.5% | 15.1% | +7.4 pp | 20.9% | +1.6 pp |
| Profit before tax | 36 | 22 | +63.5% | 32 | +11.7% |
| Net profit (PAT) | 27 | 17 | +60.5% | 25 | +7.2% |
| EPS (₹) | 0.28 | 0.18 | +55.6% | 0.26 | +7.7% |
Source: Syncom Formulations (India) Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹137 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
- Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
- Innova Captab (Q2 FY27)
Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). Key investor presentation take
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Syncom Formulations (India) Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Syncom Formulations (India) Ltd Q2 FY27 results?
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026): ₹14,821.08 lakhs (Unaudited). Quarterly EBITDA: Rs. 3,602.77 lakhs.
What is Syncom Formulations (India) Ltd share price analysis?
Syncom Formulations (India) Ltd currently shows a neutral. The stock trades at a P/E of 22.5 with a market cap of ₹1,909 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Syncom Formulations (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.